ScholarLens Back to search
2019•Unpublished venueRequires access

Real-world study of the fluocinolone acetonide implant show its benefits for treating DME

Cheryl Guttman Krader

Open publisher page 0 citations

Abstract

In the United States, the fluocinolone acetonide (FAc) 0.19 mg implant (Iluvien, Alimera Sciences) is indicated for the treatment of diabetic macular edema (DME) in patients who were previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.

About this research paper

What this paper is about

In the United States, the fluocinolone acetonide (FAc) 0.19 mg implant (Iluvien, Alimera Sciences) is indicated for the treatment of diabetic macular edema (DME) in patients who were previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the United States, the fluocinolone acetonide (FAc) 0.19 mg implant (Iluvien, Alimera Sciences) is indicated for the treatment of diabetic macular edema (DME) in patients who were previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.

Key concepts: Fluocinolone acetonide, Diabetic macular edema, Medicine, Implant, Ophthalmology, Surgery, Diabetic retinopathy, Diabetes mellitus

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Real-world study of the fluocinolone acetonide implant show its benefits for treating DME — Research Paper | ScholarLens